21 December 2016
ABOUT GLOBAL BIOENERGIES
ABOUT SYNGIP
Syngip
is a 3rd generation industrial biotech start-up
created in 2014 in the Netherlands.
It has developed a process to convert
gaseous carbon sources such as CO2, CO,
and industrial emissions such as syngas,
into various valuable chemical compounds.
To this end, the company has identified
a specific micro-organism capable of growing
using these gaseous carbon sources
as its sole feedstock, and has developed
genetic tools to allow
the implementation of artificial metabolic pathways
into it.
Its recent work has been directed to
the implementation of metabolic pathways
leading to light olefins,
major petrochemical molecules,
which include isobutene.
Economics
Here are three reasons why our process will be profitable
Because our feedstock is cheap
In most industrial biology processes,
the feedstock (generally a first generation sugar)
represents 80% of the costs.
Our feedstock is not only cheap, it is also public enemy number one.
We need to capture and transform it.
Lower cost and no food/feed versus fuel conflict,
this is a decisive competitive advantage we start with.
Because our process is cheaper
In industrial biology processes,
a large part of the non-feedstock costs corresponds to utilities.
Cooling is a serious issue: most microbes grow at moderate temperatures,
in the range of 30°C or below, and the fermentation process
creates heat that needs to be removed.
Our microbe can grow and produce at 56°C:
we can save a lot of electricity. In addition,
by targeting gaseous compounds,
we can also simplify downstream processing
Because we target big markets
Light olefins represents huge markets:
$100 billion just for propylene.
With isobutene, beyond the petrochemistry ($5 billion market),
it is the gasoline market which is opened:
isobutene can be easily transformed into isooctane,
a gasoline additive ($15 billion market),
which could even replace gasoline ($1000 billion market).
Syngip BV
Burgemeester Lemmensstraat 360
DETAILS
Global Bioenergies (Alternext Paris: ALGBE)
today signed a contribution agreement
with the shareholders of Syngip B.V.
to transfer all Syngip shares
to Global Bioenergies S.A.
The transaction's completion remains
subject to the fulfilment of several
suspensive conditions including approval
by the shareholders of Global Bioenergies.
Global Bioenergies has set
the diversification of feedstocks usable
in its isobutene process as its new R&D frontier.
CO2, CO and syngas cause global warming,
but represent
an abundant and cheap source of carbon.
Syngip's acquisition would greatly accelerate
the development of a 3rd generation isobutene process
based on the use of such resources, an aim
that has been part of Global Bioenergies' strategy
for several years.
All Syngip employees would be dedicated,
as part of the Global Bioenergies group,
to developing such a process.
Bernhard Güntner,
CEO of Syngip
"There are clear synergies
between Syngip and Global Bioenergies.
Combining our technology with Global Bioenergies'
capabilities in metabolic engineering,
industrial fermentation and chemical engineering
will be a key factor in moving to the industrialization phase.
We lose our independence, but it is worth it:
the entrepreneurial spirit that drives Global Bioenergies
on a daily basis is a very important value
for me and all of Syngip's employees".
Frédéric Pâques,
Chief Operations Officer of Global Bioenergies
"This Syngip acquisition project
is part of our general open innovation strategy,
where we look outside of our company
for technical elements to reinforce our Group."
Marc Delcourt,
CEO of Global Bioenergies
"We continue to achieve our aim
of diversifying the feedstocks usable in our process.
This acquisition will increase both
our competitiveness and our environmental impact."
Contacts
GLOBAL BIOENERGIES
François-Henri Reynaud
Chief Financial Officer
Phone: +33 (0)1 64 98 20 50
Email: invest@global-bioenergies.com
SYNGIP
Bernhard GÜNTNER
CEO
Email: bg@syngip.com
WWW.CHEMWINFO.COM BY KHUN PHICHAI
